Pulmonary tumor thrombotic microangiopathy (PTTM) is an uncommon cancer-related complication that has been most frequently reported to be associated with adenocarcinoma. We present a case of PTTM which developed in a 60-year-old man with esophageal carcinoma. One year after definitive treatment of the tumor, he developed pulmonary hypertension. Transbronchial lung biopsy (TBLB) specimens showed fibrocellular intimal proliferation and luminal stenosis of the small pulmonary vessels, which contained squamous cell carcinoma cells. Thus, PTTM associated with esophageal carcinoma was diagnosed. This is the first reported case of PTTM associated with esophageal squamous cell carcinoma. TBLB seemed to be useful for obtaining a definitive diagnosis.
Introduction
Pulmonary tumor thrombotic microangiopathy (PTTM), which was established as a disease entity by von Herbay et al in 1990 , is an uncommon cancer-related complication (1). PTTM is characterized histopathologically by widespread fibrocellular intimal proliferation causing luminal stenosis of the small pulmonary arteries and arterioles, which often contain tumor emboli and fibrin thrombi from local activation of coagulation (2). It may cause severe clinical manifestations, including pulmonary hypertension, acute cor pulmonale, and sudden death. PTTM is observed in 0.9% to 3.3% of autopsies of patients with malignant tumors (1, 3). The most common disease associated with PTTM is poorly differentiated adenocarcinoma of the stomach, and cancers other than gastric cancers are very rare. Here, we report a patient with PTTM associated with esophageal squamous cell carcinoma.
Case Report
The patient was a 60-year-old Japanese man who had a clinically significant history of cigarette smoking (Brinkman index=900) and alcohol intake (shochu 360 ml/day), and no family history of cancer. He had been diagnosed with clinical Stage IIB (T1N1M0) esophageal squamous cell carcinoma, according to the TNM classification (sixth edition) of the International Union Against Cancer (UICC) and had undergone definitive chemoradiotherapy with S-1 (tegafurgimeracil-oteracil), cisplatin, and concurrent radiation therapy at a total dose of 50.4 Gy in 28 fractions in a clinical trial. He achieved a complete response that was confirmed by repeated computed tomography (CT) scans and endoscopy with biopsy. He was subsequently seen on a regular basis for follow-up. One year after his definitive treatment, chest CT revealed multiple infiltrative shadows in the lung, and 18F-fluorodeoxyglucose positron emission tomography demonstrated hypermetabolic activity at the same sites. Although recurrence of esophageal carcinoma was suspected, a repeat CT one month later revealed that the shadows had disappeared, although new shadows had emerged (Fig. 1) . We then considered a diagnosis of inflammatory changes and decided to follow the patient carefully.
One month after the repeat CT, the patient presented with exertional dyspnea and dry cough persisting for 2 days. No abnormal breath sounds were heard on auscultation of the lung fields. Routine blood biochemistry tests were normal, except for elevated plasma C-reactive protein (6.23 mg/dL, normal <0.5 mg/dL), and the leukocyte count was normal range (Table 1) . The serum squamous cell carcinoma-related antigen level was also elevated (8.7 ng/mL, normal <1.5 ng/ dL). Arterial blood gas analysis showed mild hypoxemia. Echocardiography indicated pulmonary hypertension with tricuspid regurgitation; the estimated gradient pressure was approximately 75 mm Hg (Fig. 2) . Chest CT did not show evidence of pulmonary embolism, but revealed multiple bilateral diffuse interstitial infiltrative shadows (Fig. 3) . We initially considered several diseases, including viral or fungal infection, radiation pneumonitis, or recurrence of esophageal carcinoma. Bronchoscopy was performed to determine the cause of infiltrative shadows. Bronchoalveolar lavage did not reveal findings suggestive of infection. Transbronchial lung biopsy (TBLB) specimens from the right lower lobe showed fibrocellular intimal proliferation leading to luminal stenosis of small pulmonary vessels, which contained squamous-cell carcinoma cells. Interstitial cellular and fibrous thickening was also observed around the small vessels that had fibrocellular intimal thickening (Fig. 4) . Pulmonary tumor thrombotic microangiopathy (PTTM) was diagnosed based on the histopathological findings. Serum vascular endothelial growth factor (VEGF) was also significantly elevated to 619 pg/mL (normal<38.3 pg/mL). The patient was then treated with anticancer drugs as follows: intravenous fluorouracil for 5 consecutive days at a dose of 800 mg/m 2 and intravenous nedaplatin at a dose of 90 mg/m 2 on day 1 of a 28-day cycle. This fluoropyrimidine-based and platinum-based combination therapy was selected based on an effect of initial treatment, his condition, and approval status. He did not receive other medical treatments such as corticosteroids or anticoagulants. There were no adverse events related to the chemotherapy, but his respiratory condition gradually worsened. The patient died of respiratory failure 9 days after the start of chemotherapy, despite intensive respiratory and supportive care.
Discussion
The present patient with a history of esophageal squamous cell carcinoma developed pulmonary hypertension accompanied with dyspnea. A chest CT showed interstitial and infiltrative shadows, which was diagnosed as PTTM by TBLB. Although he was treated immediately after diagnosis, he died from respiratory failure. To our best knowledge, this is the first reported case of PTTM developing in a patient with esophageal squamous cell carcinoma.
In a study of 630 consecutive autopsies of patients with carcinoma, PTTM was found in 21 (3.3%) patients. There were 19 patients with adenocarcinoma; 11 of which had originated in the stomach (1). Suzuki et al also reported that 13 of 14 PTTM cases were associated with gastric adenocarcinoma, predominantly the diffuse type (4). The reasons why PTTM is commonly associated with adenocarcinomas and more frequently associated with gastric cancers than nongastric cancers are unknown. Although the present patient did not have gastric cancer or adenocarcinoma, the pathological features of the TBLB specimens were compatible with PTTM. Based on these findings, we diagnosed him with PTTM associated with esophageal squamous cell carcinoma.
The serum VEGF was also significantly elevated in the present patient, and increased levels of serum VEGF have been confirmed in many PTTM cases (5-8). Chinen et al reported on 6 autopsy cases of PTTM, all of which had tumor tissue cells that were positive for both VEGF and tissue factor (TF) on immunohistochemical analysis (5). These reports suggest that VEGF and TF may be involved in the pathogenesis of PTTM. However, the molecular mechanisms underlying the development of PTTM remain unknown.
Most cases of PTTM are diagnosed at autopsy, and antemortem diagnosis is extremely difficult. Various antemortem diagnostic methods have been suggested, including pulmonary wedge aspiration cytology using a Swan-Ganz catheter (9), video-assisted thoracic surgery (8), TBLB (10), and CT-guided lung biopsy (11). While the usefulness of these examinations has been reported, there have been many patients who have died without undergoing these examinations (12-14). The extremely short survival times of PTTM patients may have contributed to these deaths, as well as the difficulty of making a radiologic diagnosis based on findings that are often minimal or nonspecific.
Although PTTM is a disease with a poor prognosis, several reports have demonstrated the importance of early diagnosis and treatment. Miyano et al reported a patient with PTTM associated with gastric adenocarcinoma, who received systemic chemotherapy with S-1 and survived free of respiratory symptoms (8). In addition, Uruga et al described a patient with PTTM associated with pulmonary adenocarcinoma, who received systemic chemotherapy with carboplatin and paclitaxel, and his respiratory symptoms improved (11). These patients had not developed pulmonary hypertension, which suggests that the diagnosis and management of PTTM before pulmonary hypertension develops might be clinically important. Because the available reports suggest that patients with PTTM may be improved by anticancer treatment, we should attempt a pathological examination even if radiologic findings are not suggestive of lung metastasis.
Physicians should be aware that PTTM can develop in cancer patients, even if they do not have adenocarcinoma, and that it is important to strive for early diagnosis and appropriate treatment. Because PTTM cannot be diagnosed without histopathological examination, it is recommended to undertake the appropriate diagnostic procedures in patients with cancer or a history of cancer who present with respiratory symptoms and pulmonary shadows of unknown etiology.
